Amundi Has $4.62 Million Stake in Teleflex Incorporated $TFX

Key Points

• Amundi increased its Teleflex stake by 325.2% in the first quarter, holding 38,606 shares worth approximately $4.62 million. Institutional investors collectively own 95.62% of TFX.
• Teleflex exceeded second-quarter expectations with adjusted EPS of $1.76 and revenue of $570.3 million, while revenue rose 28.9% year over year. The company raised its fiscal 2026 EPS guidance to $6.90–$7.20, above the $6.70 analyst consensus.
• Teleflex declared a quarterly dividend of $0.34 per share, representing an annualized payout of $1.36 and a yield of about 1%. Despite the strong adjusted results, GAAP EPS and net margin remained weak, and analysts maintain a consensus “Hold” rating with a $148.90 price target.

Amundi raised its holdings in Teleflex Incorporated (NYSE:TFX - Free Report) by 325.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 38,606 shares of the medical technology company's stock after buying an additional 29,527 shares during the period. Amundi owned 0.09% of Teleflex worth $4,618,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in TFX. California State Teachers Retirement System grew its stake in shares of Teleflex by 23.2% in the first quarter. California State Teachers Retirement System now owns 51,472 shares of the medical technology company's stock valued at $6,157,000 after buying an additional 9,709 shares in the last quarter. Royal Bank of Canada increased its stake in shares of Teleflex by 16.1% during the first quarter. Royal Bank of Canada now owns 11,916 shares of the medical technology company's stock worth $1,425,000 after purchasing an additional 1,656 shares during the period. Rice Hall James & Associates LLC lifted its holdings in shares of Teleflex by 16.4% during the first quarter. Rice Hall James & Associates LLC now owns 4,721 shares of the medical technology company's stock worth $565,000 after buying an additional 664 shares in the last quarter. Renaissance Technologies LLC bought a new stake in Teleflex in the 1st quarter valued at about $6,782,000. Finally, GC Wealth Management RIA LLC bought a new stake in shares of Teleflex in the first quarter valued at approximately $1,492,000. 95.62% of the stock is owned by institutional investors.

Key Teleflex News

Here are the key news stories impacting Teleflex this week:

• Positive Sentiment: Quarterly results exceeded expectations. Teleflex reported second-quarter adjusted EPS of $1.76, topping the $1.28 consensus estimate, while revenue of $570.3 million surpassed expectations of $559.6 million. Revenue rose 28.9% year over year, providing the main catalyst for the stock’s upward move. Teleflex Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Full-year earnings guidance was raised above analyst expectations. Teleflex forecast fiscal 2026 EPS of $6.90 to $7.20, compared with the $6.70 consensus estimate. Revenue guidance of approximately $2.3 billion was broadly in line with expectations, suggesting the earnings upside is being driven primarily by profitability and execution. Teleflex Reports Second Quarter Financial Results and Full Year 2026 Outlook
• Positive Sentiment: Teleflex declared a quarterly dividend. Shareholders of record on August 14 will receive $0.34 per share on September 30. The dividend provides an annualized payout of approximately $1.36 per share and a yield of about 1%, adding modest shareholder-return support.
• Neutral Sentiment: Profitability remains mixed. GAAP diluted EPS from continuing operations was $0.96, down from $1.54 a year earlier, and the company reported a negative net margin. The adjusted EPS beat and higher outlook outweighed these concerns for investors, but the year-over-year decline remains a risk to monitor. Teleflex Posts Strong Q2 2026 Results

Teleflex Stock Up 2.1%

NYSE TFX opened at $139.61 on Friday. The business has a fifty day moving average price of $131.61 and a two-hundred day moving average price of $122.46. The stock has a market capitalization of $6.18 billion, a PE ratio of -6.12, a PEG ratio of 1.02 and a beta of 0.81. Teleflex Incorporated has a fifty-two week low of $100.18 and a fifty-two week high of $145.00. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.55 and a quick ratio of 2.03.

Teleflex (NYSE:TFX - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical technology company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.48. Teleflex had a positive return on equity of 13.29% and a negative net margin of 35.88%.The company had revenue of $570.33 million for the quarter, compared to analyst estimates of $559.59 million. During the same quarter last year, the company posted $3.73 EPS. The company's revenue for the quarter was up 28.9% compared to the same quarter last year. Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. Equities analysts expect that Teleflex Incorporated will post 6.7 earnings per share for the current fiscal year.

Teleflex Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Friday, August 14th will be paid a dividend of $0.34 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $1.36 annualized dividend and a yield of 1.0%. Teleflex's payout ratio is presently -5.96%.

Wall Street Analyst Weigh In

TFX has been the topic of a number of analyst reports. Weiss Ratings reissued a "sell (d)" rating on shares of Teleflex in a research report on Wednesday, June 24th. UBS Group began coverage on Teleflex in a report on Tuesday, July 28th. They issued a "neutral" rating and a $145.00 price objective for the company. Wall Street Zen downgraded Teleflex from a "hold" rating to a "sell" rating in a research report on Saturday, August 1st. Truist Financial reissued a "hold" rating and set a $143.00 target price (up from $135.00) on shares of Teleflex in a report on Monday, May 11th. Finally, BMO Capital Markets started coverage on Teleflex in a research report on Wednesday, July 8th. They issued an "outperform" rating and a $159.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $148.90.

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company's offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source